Search

everythinglearnresearchcommunity

for

Search:↓

A 29-year-old woman is experiencing gradual hair thinning since age 15, suspects Androgenic Alopecia, and has tried 5% minoxidil with little success. She has purchased various hair loss treatments including minoxidil, dutasteride, finasteride, and spironolactone, but is cautious about starting them due to potential interactions with her ADHD medication.

Despite using finasteride and dutasteride for years, the user experienced continued hair thinning and is now visibly balding. They are considering trying minoxidil but are doubtful about its effectiveness.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

The conversation discusses the use of topical finasteride from Hasson and Wong, with claims that none of their 800 users reported side effects. The user expresses skepticism about these claims and seeks others' experiences with the treatment.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

A user shared their 11-year journey with alopecia, using finasteride, dutasteride, and a hair transplant. They encouraged others not to panic, noting that hair miniaturization can take over 15 years to complete.

The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It highlights an interview with Stemson Therapeutics CEO Geoff Hamilton about advancements in hair cloning technology.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

A husband experiencing hair loss is considering treatments like topical minoxidil and finasteride but is concerned about their effects on his pregnant wife and future child. Alternatives suggested include oral finasteride, which is considered safe if hands are washed after use, and exploring natural methods like oils.

OP noticed fuller and thicker hair after almost 4 months of using GHK-Cu, a copper-binding peptide, through subcutaneous injections. Some users were skeptical, questioning the authenticity and potential commercial intent behind the post.

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

The user has been using liposomal topical finasteride since late 2022, progressively increasing the dose, but DHT serum levels remain largely unchanged. Despite using finasteride, minoxidil, microneedling, and ketoconazole, hair condition has neither improved nor worsened.

The user has been using a topical solution containing minoxidil and finasteride for 10 months but is not satisfied with the results, as there is no significant hair regrowth or thickening. They are questioning whether they are a non-responder or if they should continue the treatment longer.

User discusses potential hair loss cure involving growth factors from a hairy mole. Dr. Wrassman responds, saying clinical trials may happen in 2022.

Hair loss treatments like minoxidil, finasteride, TDM-105795, and PP405. MIT is hosting a hackathon to find innovative hair loss solutions.

A 7-month progress report of using finasteride and minoxidil, as well as keto dieting and derma stamping; the discussion also touched on RU58841 and its potential side effects.

A 26-year-old male with a family history of early baldness documents his hair loss journey, using finasteride, dutasteride, and Nizoral, along with lifestyle changes like weightlifting and a vertical diet. Despite some stabilization, he continues to experience thinning and remains determined to fight hair loss.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Hypoxia may enhance hair growth by stimulating stem cells, but it could also risk fibrosis. Some users humorously discuss extreme methods like choking while using minoxidil, highlighting the need for new treatments.

The conversation is about someone who has not seen hair regrowth after 6 months on finasteride alone, asking if others have experienced delayed results. Some responses indicate that results can sometimes be seen after 12 months, with full effects up to 24 months.

Topical treatments like minoxidil and finasteride are preferred for hair loss due to ease of use and natural appearance. Hair systems are considered high-maintenance and less genuine.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The user is experiencing aggressive diffuse thinning despite using 1mg oral finasteride daily, topical minoxidil twice, microneedling, and Nizoral for seborrheic dermatitis. They are considering switching to dutasteride or RU58841 but are advised to seek a second opinion to determine the cause of hair loss.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.

The user is using finasteride and minoxidil for hair loss but feels progress is slow and is considering switching to dutasteride after 12 months. They notice minor shedding but are unsure if the medication is stabilizing their hair loss.

User is experiencing hair thinning and sebum overproduction after starting finasteride and a hair growth supplement containing biotin, iron, zinc, and calcium. They suspect the finasteride might be fake but have noticed a side effect of watery semen.